Insulet (PODD) risk factors, FY2024 10-K

Risks Related to Our Business and Industry

1. 01We currently rely on sales of our Omnipod product platform to generate nearly all our revenue
2. 02If we fail to expand and maintain an effective sales force or successfully develop and maintain our relationships with intermediaries, our business, prospects, and brand may be materially and adversely affected
3. 03Our ability to grow our revenue depends in part on our retaining a high percentage of our customers
4. 04If we do not effectively manage our rapid growth, our business resources may become strained and we may not be able to deliver our products in a timely manner, which could adversely affect our results of operations
5. 05Failure to secure or retain adequate coverage or reimbursement for our products by third-party payors could adversely affect our business, financial condition, and results of operations
6. 06Healthcare reform laws could adversely affect our revenue and financial condition

Risks Related to Competition, Product Development and Intellectual Property

1. 07Our failure to compete effectively would negatively impact our revenue
2. 08As a result, we may not be able to compete effectively against these companies or their products, which may adversely impact our business
3. 09Technological breakthroughs in diabetes monitoring, treatment, or prevention could render our Omnipod products obsolete or less desirable
4. 10Our new product development initiatives may prove to be ineffective or not commercially successful
5. 11If the third parties on which we rely to conduct our clinical trials and to assist us with pre-clinical development do not perform as contractually required or expected, we may not be able to obtain regulatory clearance or approval or commercialize our products
6. 12Future market or clinical studies may be unfavorable to our Omnipod products and their efficacy, which could hinder our sales efforts and have a material adverse effect on our business, results of operations, financial condition, and cash flows
7. 13We may be unable to adequately protect our intellectual property rights
8. 14Claims that our current or future products infringe or misappropriate the proprietary rights of others could adversely affect our ability to sell those products and cause us to incur additional costs
9. 15We rely on agreements or licenses to intellectual property or other rights in order to sell our current product and commercialize new products

Risks Related to Economic Conditions and Operating Internationally

1. 16The continuing worldwide macroeconomic and geopolitical uncertainty as well as the impact of global pandemics may adversely affect our business and prospects
2. 17Another global pandemic could adversely impact our business and financial condition
3. 18Our financial condition or results of operations may be adversely affected by international business risks
4. 19Failure to comply with the U.S. Foreign Corrupt Practices Act and similar worldwide anti-bribery laws could materially adversely affect our business and result in civil and/or criminal sanctions

Risks Related to Supply Chain, Operations, and Drug Delivery

1. 20Our inventory is produced and maintained in a limited number of locations
2. 21We are dependent upon third-party suppliers, making us vulnerable to supply problems and price fluctuations, and we may not be able to obtain sufficient components or raw materials on a timely basis or at all
3. 22Our manufacturing process is highly complex and subject to regulation; as demand for our products increase, we may experience manufacturing difficulties, including not effectively managing the start-up of new manufacturing lines or issues with our third-party contract manufacturer, which could harm our business
4. 23Our non-insulin Drug Delivery product line faces challenges which, if not met, may impair its future success

Risks Related to Government Regulation and Litigation

1. 24We are subject to extensive government regulation, which could restrict the sales and marketing of our products, could cause us to incur significant costs, and impact our profitability and competitiveness
2. 25The occurrence of any of these events may have a material adverse effect on our business, financial condition, and results of operations
3. 26If we, our contract manufacturer or our component suppliers fail to comply with the FDA’s quality system regulations, the manufacturing and distribution of our devices could be interrupted, and our sales and operating results could suffer
4. 27Malfunction of our products could lead to recalls or safety alerts or litigation and have a significant adverse impact on us
5. 28We may be subject to enforcement action if we engage in improper marketing or promotion of our products
6. 29If we fail to comply with Medicare, Medicaid, fraud and abuse, and other healthcare regulations, we could be subject to substantial penalties and/or be excluded from participation in government programs

Risks Related to Information Technology, Privacy and Security

1. 30We rely on the proper function, availability, and security of our product and information technology systems; a successful cyber-attack or other breach or disruption of our product or these systems could have a material adverse effect on our business and results of operations
2. 31Failure to maintain the privacy and security of our customer, third-party payor, employee, supplier, or Company information could result in substantial costs and/or subject us to litigation, enforcement actions, and reputational damage
3. 32The rapidly-changing technical and regulatory environment and our AI-related activities may have an adverse effect on our business

Risks Related to Our Debt

1. 33Our Credit Agreement imposes restrictions on us that may adversely affect our ability to operate our business
2. 34Conversion of any of our Convertible Senior Notes may dilute the ownership interest of existing stockholders or depress our stock price

General Risks

1. 35Our success depends on our ability to attract, motivate, and retain key personnel
2. 36Acquisitions or investments in new businesses, products, or technologies could disrupt our business
3. 37We may need to raise additional funds in the future, and these funds may not be available on acceptable terms or at all
4. 38The price of our common stock may be volatile
5. 39Changes in tax laws or exposures to additional tax liabilities could negatively impact our operating results
6. 40A material weakness in our internal control over financial reporting could result in material misstatements in our financial statements and cause us to fail to meet our reporting and financial obligations